NCT04258683: Phase 2: Pembrolizumab Added to the Standard First-Line therapy (CyBorD) for NDMM NTE

NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

NCT04258683: Phase 2: A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed patients with multiple myeloma that are not eligible for autologous stem cell transplantation.

Sponsor

Canadian Myeloma Research Group

Collaborator

Merck Sharp & Dohme LLC

---

ClinicalTrials.gov Identifier: NCT04258683

Official Title: A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation

First Posted : February 6, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: Pembrolizumab

---

Locations

Canada, Manitoba

Canada, New Brunswick

Canada, Quebec

Canada, Saskatchewan